Biolab Farmacêutica expands portfolio with therapy for heart failure
Leader in cardiology, pharmaceutical company now offers medicine for condition that affects 2 million Brazilians
Biolab Farmacêutica, one of the ten largest companies in the sector in the country and a leader in cardiovascular health medicines, is expanding its operations in cardiology with the molecular combination of sacubitril/valsartan. The drug has been added to its portfolio as a treatment option for approximately 2 million Brazilians who live with heart failure (HF), according to data from the Ministry of Health.[i]
The heart failure (HF) scenario in Brazil is critical, with around 240,000 new cases recorded every year. The condition, characterized by the inability of the heart muscle to pump blood with the necessary force, imposes severe physical limitations on patients, such as shortness of breath, swelling and extreme fatigue. Between 2011 and 2021, SUS recorded more than 2.5 million hospitalizations for the disease[ii], But the challenge persists even after leaving hospital: the post-discharge prognosis remains worrying, with 50% of patients being readmitted within 90 days of discharge. [iii]
In this context, the new treatment offered by Biolab Farmacêutica, from the class of INRAs - Neprilysin and Angiotensin Receptor Inhibitors, focuses on reducing mortality and hospitalizations. [iv]The therapy works in two ways by relaxing the blood vessels and eliminating excess fluids, reducing the heart's workload.[v]
“To ensure that this medicine reaches those who need it, we will use our visitation force to provide support and scientific information to more than 40,000 doctors, including cardiologists, endocrinologists, geriatricians and general practitioners throughout Brazil. The increase in Brazilian life expectancy brings the challenge of managing chronic diseases more efficiently. Our response is to offer innovation that simplifies the patient's journey and to expand our role in medical education, making treatment more accessible,” says Fabio Amorosino, CEO of Biolab & Co.
The launch of the drug in Brazil is the result of a strategic co-marketing partnership between Biolab and Novartis. This union combines Biolab's market strength and capillarity with Novartis' global expertise in innovation, accelerating access for patients and doctors to state-of-the-art treatments for heart health.
- [i] Cestari VRF et al. Spatial distribution of heart failure mortality in Brazil, 1996-2017. Arquivos Brasileiros de Cardiologia. 2021;118(1):41-51. doi: 10.36660/abc.20201325
- [ii] https://www.gov.br/conitec/pt-br/midias/consultas/relatorios/2024/sociedade/relatorio-para-a-sociedade-476-dave#:~:text=Estima%2Dse%20que%20a%20insufici%C3%AAncia%20card%C3%ADaca%20afete%2026,240%20mil%20casos%20novos%20a%20cada%20ano
- [iii] De Albuquerque DC, De Barros E Silva PGM, Lopes RD, Hoffmann-Filho CR, Nogueira PR, Reis H, Nishijuka FA, Martins SM, De Figueiredo Neto JA, Pavanello R, De Souza Neto JD, Danzmann LC, Gemelli JR, Rohde LEP, Hernandes ME, Rivera MAM, Simões MV, Dos Santos ES, Canesin MF, Zilli AC, Santos RHN, Jesuino IA, Mourilhe-Rocha R, Moura LZ, Marcondes-Braga FG, Mesquita ET; BREATHE INVESTIGATORS. In-Hospital Management and Long-term Clinical Outcomes and Adherence in Patients With Acute Decompensated Heart Failure: Primary Results of the First Brazilian Registry of Heart Failure (BREATHE). J Card Fail. 2024 May;30(5):639-650. doi: 10.1016/j.cardfail.2023.08.014. Epub 2023 Aug 28. PMID: 37648061
- [iv] Lewis EF, Claggett BL, McMurray JJV, Packer M, Lefkowitz MP, Rouleau JL, Liu J, Shi VC, Zile MR, Desai AS, Solomon SD, Swedberg K. Health-Related Quality of Life Outcomes in PARADIGM-HF. Circ Heart Fail. 2017 Aug;10(8):e003430. doi: 10.1161/CIRCHEARTFAILURE.116.003430. PMID: 28784687.
- [v] Pascual-Figal D, Bayés-Genis A, Beltrán-Troncoso P, et al. Sacubitril-Valsartan: Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. Frontiers in Cardiovascular Medicine. 2021;8:754499. doi: 10.3389/fcvm.2021.754499